left bladder wall (RBW, LBW), bladder dome (BD) and prostatic urethra (PU). Multivariate Cox regression analysis was done to determine predictive factors for recurrence, progression, death due to BCa and diagnosis of UTUC RESULTS: A total of 139 T1G3 patients were included in this analysis. Mean age was 67.8 (9.5) years and 123 (88%) were male. CONCLUSIONS: CIS in T1G3 patients is a common finding with a similar distribution in all the bladder regions. Patients with CIS in PU or BD had a worse prognosis, suggesting the importance of the location of CIS as prognostic factor in patient with high risk NMIBC. According to our findings, a routine evaluation of the entire bladder with standardized multiple biopsies is mandatory in primary high grade NMIBC.
INTRODUCTION AND OBJECTIVES:
Previous studies defined biochemical response (BR) to salvage radiotherapy (SRT) as a first PSA after SRT <0.2 ng/ml. However, the entity of early PSA response may be a more sensitive end-point of clinical progression as shown in the setting of systemic treatments. We hypothesized that the optimal definition of BR to SRT vary according to PSA at SRT. METHODS: We included 450 patients treated with local radiation to the prostatic and seminal vesicle bed for PSA rising after radical prostatectomy. The definition of BR was based on the first post-SRT PSA. No patient received concomitant HT. To combine the impact of pre-and post-SRT PSA levels, we defined "PSA decrease ratio" (PSADR): ((PSA at SRT -First PSA after SRT) / PSA at SRT)*100. The outcome was clinical recurrence (CR), defined by positive imaging at follow-up. Cox regression analysis was used to develop a base model that included pT stage, pathological Gleason score, and PSA at SRT. The optimal PSADR cut-off was defined using the multivariable function Lowess. Two BR definitions were compared: (1) post-SRT PSA <0.2 ng/ml; (2) optimal PSADR cut-off. Decision curve analysis provided an estimate of the net benefit obtained using the two definitions (Model 1 vs Model 2). The accuracy of the models was assessed using the AUC.
RESULTS: Median (IQR) PSA pre-SRT was 0.40 (0.22, 0.69) ng/ml. Median (IQR) PSA post-SRT was 0.10 (0.02, 0.23) ng/ml. Median (IQR) PSADR was 75% (44, 94). At a median follow-up of 79 months, 67 (15%) patients developed CR. Using the Lowess function, we identified PSADR >0% as the optimal cut-off for BR (Figure 1a) , which equals to any post-SRT PSA drop of at least 0.1 ng/ml compared to the pre-treatment PSA. We observed BR in 329 (73%) patients using definition #1 (post-SRT PSA <0.2 ng/ml), and in 396 (88%) patients using definition #2 (PSADR >0%). At decision curve analysis, Model 2 showed higher clinical net benefit compared to Model 1 (Figure 1b) . The AUC of Model 2 was higher as compared to Model 1 (AUC 75% vs. 71%, p[0.001).
CONCLUSIONS: Any PSA drop !0.1 ng/ml in the first PSA after SRT represented the most accurate definition of BR to SRT. This new definition out-performed the current definition based on post-SRT PSA only and should be validated in future studies.
Source of Funding: None

MP22-02 GNRH ANTAGONISTS HAVE DIRECT INHIBITORY EFFECTS ON CASTRATION-RESISTANT PROSTATE CANCER VIA INTRACRINE ANDROGEN AND AR-V7 EXPRESSION
Vito Cucchiara*, Joy Yang, Chengfei Liu, Sacramento, CA; Hans Adomat, Emma Guns, Martin Gleave, Vancouver, Canada; Allen Gao, Christopher Evans, Sacramento, CA INTRODUCTION AND OBJECTIVES: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer (PCa). Degarelix (Firmagon, Deg), a GnRH receptor antagonist demonstrated some advantages over the LHRH agonist Leuprolide (Leup) by avoiding "testosterone flare" and lower FSH levels. We compared the effect of Deg and Leup on prostate cancer (PC) cell progression in vitro and in vivo.
METHODS: RT-qPCR was conducted for GnRH type 2 receptor in PC cell lines. PSA-Luc assays were performed coupled with or without AR-V7 transfection in C4-2B cells. PC cell proliferation in the presence of Leup and Deg was evaluated by cell counts. Western blotting analysis and RT-qPCR were performed to examine the levels of AR-FL and AR variants (V7) upon treatments with Leup and Deg alone or in combination with antiandrogens (abiraterone acetate, AA or enzalutamide, Enza). In vivo VCaP xenographs were treated with control, castration, Leup or Deg in a 6-week period of time. Tumor progression was monitored by biweekly calliper measurement.
